11.8.2- OCULAR DIAGNOSTIC AND POST OPERATIVE PREPARATIONS

46/15.   Aflibercept (BNF )- ( EYLES) - BAYER -Ocular diagnostic agent

Active Ingredient-        Aflibercept   (BNF )-  

Indication-                  Fot treatment of the eye- specists use only for the treatment                                        treatment of neovascular macular deneration

 Cautions-                   monitor intr-ocular pressure following injection , patients at                                             risk or retinal pigment epithelial trear

Contra-indications-     ocular or periocular infection,severe intra-ocular                                                             inflammation,clinical signs of irrevrsible ischemic visual                                            function loss 

Pregnancy-                   manufacturer advices avoid unless potential benefit                                                   outweighs risk and recommends women use effective                                                   contraception during and for atleast 3 months                                                               after  treatment                                   

Side effects-             conjuntival haemorrhage, corneal errosion

Dose-                         Neovascular (wet) age related defeneration by intravitreal                                           injection- Adult- over 18 years 2mg  into the affected eye once                                     a month for 3 months

                                 Mascular oedema secondary to central retinalvein occlusion                                       by    intra vitreal injection-                                                                                                 Adult- over 18 years- 2mg into the affected eye once a month,                                       monitor visual and anatomic outcomes monthly.                                                          Continue treatment until visual and anatomic outcomes are                                         stable for 3 months ascessment monthly                                                                                         

11.8.2- OCULAR DIAGNOSTIC AND POST OPERATIVE PREPARATIONS

47/15.   Pegaptanib sodium- (BNF 68)- Mugagen -PFIZER -Ocular diagnostic agent

Active Ingredient- - Pregaptanib sodium 

Indications- macular  degeneration

Cautions- monitor intraocular pressure following injections patients at risk of                             retinal pigment epithelial tear

Contra-indications- ocular periocular infection, severe intr-0cular pressure folloing injction

Pregnancy-     adviced avoid unlss potential benfit outweigh risks and                                                 recommends women us effective contrception during and for at                               

Side effects-     conjtivial haemorrhage,vitrous heamorrhage corneal errosion

Dose-               neovscular wt relatred macular degeneration by intr venous inj only                        adult over 18 yrs 2mg into the affected eye once a month monitor                            visual and anatomic outcome monthly continue treament otcomes for                      3  months                                                     

11.8.2- OCULAR DIAGNOSTIC AND POST OPERATIVE PREPARATIONS

48/15.   Ranibizumab (BNF )- (LUCENTIS)- NOVARTIS-  Ocular diagnostic agent

Active Ingredient-        -   Ranibizumab (BNF )- Indication- For the treatment of the                                             eye- spelists use only- option for treatment of visual                                                     impairment due to biabetic maular oedema only if the eye                                           has a central retinal thichmess

 Cautions-                  Histoty of stoke or transcient idschemic attack, patients at                                         risk  of retinal pigment epithelial tear, monitor intra-ocular                                            pressure,  perfusion of the optic nerve head,  and signs of                                          ocular infection.

Contra- indications-  ocular or periocular infection, severe intra-ocular                                                             inflammation, sgns of irevrsible ischemic visual funSction                                           loss in patients with retinal vein occlusion

Pregnancy-               manufacture adevices avoid unless benefit outweig  effetive                                        and rcommends women use effective contrcepton during and                                    at least for 3 months after treatment 

Breast feeding-       manufacturer reccond avoid- as no information available

Side effects-           n,ausea, headache, nasopharyngatic, cough, anxiety, urinary                                        tract infection, arthalgia, raised intra-oculat pressure, visual                                       disturbances, conjuntivial,  retinaland vitreous disordersse-

Dose-                      Neovascular wet age related mascular degeneration by                                                intrvitral   injetion                                                                                                               Adult- over 18 years  500mg once a month into the affected eye,                                  monitor visual acuty monthly, is stable for at least 3 monhs,                                    therafter monitor for 3 consecutive months therfter monitor                                       visual  aculty monthly        

                            Diabtic macular edema- by intrvitreal injection,                                                              Adult over 18 year 500mg once a month into the affecte eye,                                        monitor visual acuityy is stable for tleast 3 months. discontinue                                 treatment if no improvement is  noticed

11.8.2- OCULAR DIAGNOSTIC AND POST OPERATIVE PREPARATIONS

49/15.  VERTEPORFIN - (BNF 68)- Visodyne -NOVARTIS -Ocular diagnostic agent

Active Ingredient-   Visodynes- during infusion

Indications-              by specialist use only - wet age related macular degeneration

Cautions-                photosensitivity- avoid exposure of unprotected skin and eyes                                   to  right  light during infusion and for 48 hours afterwards,                                          concomittant use with other photosensitising drugs ,biliary                                        obstructions, avoid extrvasation

Contra-indications-  acute  porphyria

Hepatic impairment-  use with caution in moderatavoid breast feedinge                                                       impairment, avoid in severe  impairment     

Pregnancy-            manufacturer advices use only if the potential  outweighs                                            risk (tetragonenic in animal studies)   

Breast feeding-       no inform available.manufacture advices    avoid ,breast                                                  feeding  foacuityr 48 hours after admininistration            

Side effects-          nausea, . , malaise, back painsitivity, visual                                 disturbances including reduced visual acuity, flashing lights,                                     visual field defects, less commonly hypertension 

Dose-                    by intravenous infusion over 10 minutes,6mg/m2 

11.8.2- OCULAR DIAGNOSTIC AND POST OPERATIVE PREPARATIONS

50/15.  OCRIPLASTIN  - (BNF 68)-  Jetrea- ALCON-  Ocular diagnostic agent

Indications-              by specialist use only - 

Cautions-                 monitor intr-Ocular pressure, visual acutivity, and for signs of                                           intra-ocuular inflammation or infection following                                                            injections

Contr-indications- active or  suspected ocular periocular infection

Peganancy-         manufacture advices use if the potential benefit outweighs risks

Breast feeding-  adviced to use if the potential benefit outweighs the risk

Side effects-  comjuntivial retinal and vitrous disorders, reduced acuity, raised intr-ocular pressure, macular hole, macular degeneariion, macular edema

 Dose-                by intra-vetreal injection- adult over 18 years- 125mg as a single                                  dose into the affected eye